Imbruvica (ibrutinib) capsules, 140mg (YJ code: 4291043M1027, standard: 140mg 1 capsule), manufactured by Janssen Pharmaceutical, are an anticancer medicine indicated for treating certain blood cancers like mantle cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and Waldenström’s macroglobulinemia. It functions as a Bruton’s tyrosine kinase (BTK) inhibitor, blocking a protein essential for cancer cell growth and survival.
Imbruvica capsules 140mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).